Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers

Sridevi Addanki, Salyna Meas, Vanessa Nicole Sarli, Balraj Singh, Anthony Lucci

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Liquid biopsies allow for the detection of cancer biomarkers such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Elevated levels of these biomarkers during cancer treatment could potentially serve as indicators of cancer progression and shed light on the mechanisms of metastasis and therapy resistance. Thus, liquid biopsies serve as tools for cancer detection and monitoring through a simple, non-invasive blood draw, allowing multiple longitudinal sampling. These circulating markers have significant prospects for use in assessing patients’ prognosis, monitoring response to therapy, and developing precision medicine. In addition, single-cell omics of these liquid biopsy markers can be potential tools for identifying tumor heterogeneity and plasticity as well as novel therapeutic targets. In this review, we focus on our current understanding of circulating tumor biomarkers, especially in breast cancer, and the scope of novel sequencing technologies and diagnostic methods for better prognostication and patient stratification to improve patient outcomes.

Original languageEnglish (US)
Article number7843
JournalInternational journal of molecular sciences
Volume23
Issue number14
DOIs
StatePublished - Jul 2022

Keywords

  • circulating tumor cells
  • circulating tumor DNA
  • diagnosis
  • early stage breast cancer
  • late-stage breast cancer
  • liquid biopsy
  • next generation sequencing
  • screening

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Fingerprint

Dive into the research topics of 'Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers'. Together they form a unique fingerprint.

Cite this